We are live on ! Find out more
ADMS

Adamas Pharmaceuticals
ADMS

Delisted

ADMS was delisted on the 23rd of November, 2021.

Back to rankings

63 hedge funds and large institutions have $52.9M invested in Adamas Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more capital invested

Capital invested by funds: $33.5M → $52.9M (+$19.4M)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

3% more funds holding

Funds holding: 61 → 63 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

52% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 25

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
1.27%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
12
Reduced
25
Closed
11
Calls
$141K
Puts
–
Net Calls
+$141K
Net Calls Change
+$104K

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$2.04M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$1.59M
3
EIM
Essex Investment Management
Massachusetts
+$1.27M
4
Two Sigma Investments
Two Sigma Investments
New York
+$538K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$396K

Top Sellers

Rank Fund Capital Flow
1
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$1.22M
2
AQR Capital Management
AQR Capital Management
Connecticut
-$1.08M
3
N
Nuveen
North Carolina
-$945K
4
BOS
Bingham Osborn & Scarborough
California
-$533K
5
Jane Street
Jane Street
New York
-$445K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$11.3M – – –
OM
2
Opaleye Management
Massachusetts
$6.13M +$2.04M +527,800 +55%
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.84M – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$3.4M -$148K -38,250 -4%
SCM
5
Stonepine Capital Management
Oregon
$2.71M -$388K -100,237 -13%
Assenagon Asset Management
6
Assenagon Asset Management
Luxembourg
$2.7M -$366K -94,691 -13%
EA
7
Emerald Advisers
Pennsylvania
$2.65M -$104K -26,816 -4%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$2.45M +$1.59M +409,847 +223%
BlackRock
9
BlackRock
New York
$2.19M -$260K -67,151 -11%
DAM
10
Deltec Asset Management
New York
$1.47M – – –
EIM
11
Essex Investment Management
Massachusetts
$1.36M +$1.27M +329,437 New
EMFAT
12
Emerald Mutual Fund Advisers Trust
Pennsylvania
$1.27M -$1.22M -314,326 -51%
Morgan Stanley
13
Morgan Stanley
New York
$1.23M -$189K -48,876 -14%
WVP
14
Worth Venture Partners
New Jersey
$927K -$72K -18,600 -8%
Acadian Asset Management
15
Acadian Asset Management
Massachusetts
$925K +$396K +102,283 +84%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$725K +$191K +49,287 +39%
BBA
17
Baker Bros. Advisors
New York
$675K -$34K -8,800 -5%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$649K – – –
Two Sigma Investments
19
Two Sigma Investments
New York
$573K +$538K +139,059 New
BCM
20
Bridgeway Capital Management
Texas
$515K -$232K -60,000 -32%
HVC
21
Healthcare Value Capital
New Jersey
$412K +$387K +100,000 New
MFW
22
Mosaic Family Wealth
Missouri
$381K -$2.48K -640 -0.7%
Two Sigma Advisers
23
Two Sigma Advisers
New York
$372K +$275K +71,100 +370%
Squarepoint
24
Squarepoint
New York
$339K +$280K +72,336 +721%
Northern Trust
25
Northern Trust
Illinois
$293K +$12.7K +3,277 +5%
1
2 3

ADMS Hedge Fund Activity: Q3 2020 in Review

63 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2020, worth a combined $52.9M — up 58% from $33.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ADMS positions and 11 closed out — a net gain of 2 holders — while 12 added to existing stakes and 25 trimmed.

The largest buyer was Opaleye Management, adding an estimated $2.04M. The largest seller was Emerald Mutual Fund Advisers Trust, cutting an estimated $1.22M.

  • 63 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2020, up from 61 in Q2 2020.
  • Funds reported $52.9M of Adamas Pharmaceuticals stock for Q3 2020, up 58% quarter-over-quarter.
  • 13 funds opened new Adamas Pharmaceuticals positions in Q3 2020 and 11 closed out, a net change of +2 holders.
  • The largest Adamas Pharmaceuticals buyer in Q3 2020 was Opaleye Management, an estimated $2.04M added.
  • The largest Adamas Pharmaceuticals seller in Q3 2020 was Emerald Mutual Fund Advisers Trust, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2020.